Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

e antigenic challenge phase, no differences in the AE profile between the SparVax(TM) dose groups were noted.

Both vaccines were immunogenic following the 3-dose series with response rates of approximately 90%. There were no significant differences in either TNA or ELISA geometric mean titers (GMT) between the vaccine groups 14 days after the third vaccination. A strong immunologic memory response was observed at both 6 months and 12 months and no differences were seen between SparVax(TM) groups in terms of response rate or GMT measured by TNA.

The study concluded that SparVax(TM) was safe, well-tolerated and produced antibody responses comparable to the currently licensed product. The lower incidence of injection site reactions observed with SparVax(TM) may indicate that it is better tolerated than BioThrax(R), with good immunologic memory demonstrated after antigen exposure at 6 or 12 months.

"This is an important finding and supports the rationale for stockpiling a highly purified second generation anthrax vaccine utilizing modern vaccine technology as described in the March 2002 Institute of Medicine report, The Anthrax Vaccine: Is It Safe; Does it Work?," said Mr. Wright.

The SparVax(TM) Phase II clinical trial has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health.

Conference Call and Webcast Information

PharmAthene management will host a conference call to provide an update on the SparVax(TM) program on Wednesday, April 29, 2009, at 4:30 p.m., E.T. The dial-in number for U.S. callers is 1-866-788-0540 and for international callers is 857-350-1678. The participant passcode is 82129094.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. E.T. on April 29, 2009 until approximately 11:59 p.m. E.T. May 29
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... NY , April 23, 2015 /PRNewswire/ - Crystal ... an Executive Informational Overview ® (EIO) on Aeterna ... 52-page report is available on Crystal Research Associates, website ... on Aeterna Zentaris, website at www.aezsinc.com . ... into a specialty biopharmaceutical company in oncology, endocrinology, and ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
(Date:4/22/2015)... SEATTLE , April 22, 2015   ... startup, today announced $1.6M in Series A financing ... investor. The funding helps accelerate consumer and employer ... scores covering surgeries at over 4,800 U.S. hospitals. ... surgery, you are probably very concerned about choosing ...
Breaking Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2
... Sciences Inc., a privately held,biopharmaceutical company that specializes ... pharmaceuticals, today reported,that enrollment has begun for a ... Iluvien(TM) in patients with bilateral geographic atrophy (GA) ... The pilot study will ...
... Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... for the early detection of diseases and personalized ... into a agreement allowing Centocor Research & Development, ... genomic biomarker program. Additional terms of the agreement ...
... LOURES, Portugal, December 11 Hovione announced today,that it ... Ingredients (API) site in Ireland. This site manufactures,intermediates for ... The site has had a number of ... & Welch, Warner Lambert, Pfizer and now Hovione. Over,the ...
Cached Biology Technology:Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2GeneNews provides Centocor access to its osteoarthritis program 2Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Reusing the major greenhouse gas carbon dioxide (CO2) from industrial ... environment is on the verge of becoming a commercial ... in the U.S. are leading the way, according to an ... newsmagazine of the American Chemical Society. Alex Scott, C&EN,s ...
... contact during early infancy may be a key to early ... National Institute of Mental Health (NIMH), part of the National ... Nature , the study reveals the earliest sign of developing ... within the first two to six months of life. ...
... Texas Medical Branch at Galveston have discovered one of the ... the Journal of Biological Chemistry . While ... cardiomyopathy develops is not well understood, other than that it ... a family of enzymes that controls the functions of other ...
Cached Biology News:Earliest marker for autism found in young infants 2Earliest marker for autism found in young infants 3Research reveals possible cause of diabetic cardiomyopathy 2
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: